Abstract
Androgens via their cognate receptor may be involved in the development and progression of prostate cancer. The aim of this study was to determine whether tea polyphenols have inhibitory effects on androgen action in an androgen-responsive, prostate cancer cell line, LNCaP. The tea polyphenol, EGCG, inhibited LNCaP cell growth and the expression of androgen regulated PSA and hK2 genes. Moreover, EGCG had a significant inhibitory effect on the androgenic inducibility of the PSA promoter. Immunoblotting detected a decrease in androgen receptor protein with treatments of the tea polyphenols EGCG, GCG and theaflavins. Northern blot analysis showed decreased levels of androgen receptor mRNA by EGCG. Transient transfections demonstrated that EGCG and theaflavins could repress the transcriptional activities of the androgen receptor promoter region. An Sp1 binding site in the androgen receptor gene promoter is an important regulatory component for its expression. This study suggests Sp1 is the target for the tea polyphenols because treatments of EGCG decreased the expression, DNA binding activity and transactivation activity of Sp1 protein. In conclusion, we have described a new property of tea polyphenols that inhibits androgen action by repressing the transcription of the androgen receptor gene.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ahmad N, Feyes DK, Nieminen A-L, Agarwal R and Mukhtar H . 1997 J Natl Cancer I 89: 1881–1886
Alroy I, Soussan L, Seger R and Yarden Y . 1999 Mol Cell Biol 19: 1961–1972
Andrews PE, Young CYF, Montgomery BT and Tindall DJ . 1992 Cancer Res 52: 1525–1529
Blok LJ, de Ruiter PE and Brikmann AO . 1996 Endocr Res 22: 197–219
Blok LJ, de Ruiter PE and Brikmann AO . 1998 Biochemistry 37: 3850–3857
Blot WJ, Chow WH and McLaughlin JK . 1996 Eur J Cancer Prev 5: 425–438
Brawer MK and Ellis WJ . 1995 Cancer 75: 1783–1789
Charlesworth MC, Young CYF, Klee GG, Saedi MS, Mikolajczyk SD, Finlay JA and Tindall DJ . 1997 Urology 49: 487–493
Chen S, Supakar PC, Vellanoweth RL, Song CS, Chatterjee B and Roy AK . 1997 Mol Endocrinol 11: 3–15
Chomazynski P and Sacchi N . 1987 Anal Biochem 162: 156–159
Culig Z, Hobisch A, Hittmair A, Peterziel H, Cato ACB, Bartsch G and Klocker H . 1998 The Prostate 35: 63–70
Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Young CYF, Klee GG, Tindall DJ and Bostwick DG . 1997 Urology 49: 857–862
Dorgan JF, Judd JT, Longcope C, Schatzkin A, Clevidence BA, Campbell WS, Nair PP, Franz C, Kahle L and Taylor PR . 1996 Am J Clin Nutrition 64: 850–855
Feigl P, Blumenstein B, Thompson I, Crowley J, Wolf M, Kramer BS, Coltman Jr CA, Rrawley OW and Ford LG . 1995 Control Clin Trials 16: 150–163
Fleshner NE and Trachtenberg J . 1995 J Urol 154: 1642–1646
Gann PH, Hennekens CH, Ma J, Longcope C and Stampfer MJ . 1996 J Natl Cancer I 88: 1118–1126
Gregory CW, Hamil KG, Hall SH, Pretlow TG, Mohler JL and French FS . 1998 Cancer Res 58: 5718–5724
Gupta S, Ahmad N, Mohan RR, Husain MM and Mukhtar H . 1999 Cancer Res 59: 2115–2120
Hamalainen E, Adlercreutz H, Puska P and Pietinen P . 1984 J Steroid Biochem 20: 459–464
Hsieh M-L, Charlesworth MC, Goodmanson M, Zhang S, Seay T, Klee GG, Tindall DJ and Young CYF . 1997 Cancer Res 57: 2651–2656
Huggins C and Hodges CV . 1941 Cancer Res 1: 293–297
Kaisary AV, Tyrrell CJ, Beacock C, Lunglmayr G and Debruyne F . 1995 Eur Urol 28: 215–222
Kemppainen JA, Lane MV, Sar M and Wislon EM . 1992 J Biol Chem 267: 968–974
Kemppainen JA and Wilson EM . 1996 Urology 48: 157–163
Koivisto P, Kolmer M, Visakorpi T and Kallioniemi OP . 1998 Am J Pathol 152: 1–9
Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T and Kallioniemi OP . 1997 Cancer Res 57: 314–319
Koivisto P, Visakorpi T and Kallioniemi OP . 1996 Scand J Clin Lab Invest 56: 57–64
Krongrad A, Wilson CM, Allman DR and McPaul MJ . 1991 Mol Cell Endocrinol 76: 79–88
Labrie F, Belanger A, Dupont A, Luu-The V, Simard J and Labrie C . 1993 Clin Invest Med 16: 475–492
Liao S and Hiipakka RA . 1995 Biochem Biophysl Res Comm 214: 833–838
Liao S, Umekita Y, Guo J, Kokontis JM and Hiipakka RA . 1995 Cancer Lett 96: 239–243
Lindzey J, Kumar MV, Grossmann M, Young CYF and Tindall J . 1994 Vitam Horm 49: 383–432
Mizokami A and Chang C . 1994 J Biol Chem 269: 25655–25659
Montgomery BT, Young CYF, Bilhartz DL, Andrews PE, Prescott JL, Thompson NF and Tindall DJ . 1992 The Prostate 21: 63–73
Paschka AG, Butler R and Young CYF . 1998 Cancer Lett 130: 1–7
Philipsen S and Suske G . 1997 Nucleic Acids Res 27: 2991–3000
Pienta KJ and Esper PS . 1993 Ann Intern Med 118: 793–803
Ryu SJ, Zhou S, Ladurner AG and Tjian R . 1999 Nature 397: 446–450
Soloway MS and Matzkin H . 1993 Cancer 71: 1083–1088
Spitzweg C, Zhang S, Bergert ER, Castro MR, Mclver B, Heufelder AE, Tindall DJ, Young CYF and Morris JC . 1999 Cancer Res 59: 2136–2141
Stoner GD and Mukhtar H . 1995 J Cell Biol Chem S22: 169–180
Takane KK and McPhaul MJ . 1996 Mol Cell Endocrinol 119: 83–93
Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN and Balk SP . 1995 New Engl J Med 332: 1393–1398
Thompson L, Feigl P and Coltman C . 1995 Important Advances in Oncology Chemoprevention of Prostate Cancer with Finasteride De Vita Jr VT, Hellman S and Rosenberg SA eds. JB Lippincott Company Philadelphia pp 57–76
Trapman J and Cleutjens KBJM . 1997 Semin Cancer Biol 8: 29–36
Van laar JH, Berrevoets CA, Trapman J, Zegers ND and Brinkmann AO . 1991 J Biol Chem 266: 3734–3738
Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J and Kallioniemi OP . 1995 Nature Genetics 9: 401–406
Zhang S, Hsieh M-L, Zhu W, Klee GG, Tindall DJ and Young CYF . 1999 Endocrinology 140: 1665–1671
Zhang S, Murtha PE and Young CYF . 1997a Biochem Biophysl Res Comm 231: 784–788
Zhang J, Zhang S, Murtha PE, Zhu W, Hou SS and Young CYF . 1997b Nucleic Acids Res 25: 3143–3150
Zhou ZX, Lane MV, Kemppainen JA, French FC and Wilson EM . 1995 Mol Endocrinol 9: 208–218
Acknowledgements
This work is partly supported by the NIH grants DK 41995 and CA 70982.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ren, F., Zhang, S., Mitchell, S. et al. Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene 19, 1924–1932 (2000). https://doi.org/10.1038/sj.onc.1203511
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203511
Keywords
This article is cited by
-
Phytochemistry of Prunus africana and its therapeutic effect against prostate cancer
Comparative Clinical Pathology (2022)
-
An Asian traditional herbal complex containing Houttuynia cordata Thunb, Perilla frutescens Var. acuta and green tea stimulates hair growth in mice
BMC Complementary and Alternative Medicine (2017)
-
Reduced prostate cancer risk with green tea and epigallocatechin 3-gallate intake among Hong Kong Chinese men
Prostate Cancer and Prostatic Diseases (2017)
-
Resveratrol Represses Pokemon Expression in Human Glioma Cells
Molecular Neurobiology (2016)
-
Recent progress on nutraceutical research in prostate cancer
Cancer and Metastasis Reviews (2014)